AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 172 min read$ALKS

Nichols Christian Todd sold $373K of ALKS

Nichols Christian Todd (SVP, Chief Commercial Officer) sold 7,576 shares of Alkermes plc. (ALKS) at an average of $49.23 ($49.19–$49.65, $0.37M total) across 2 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Nichols Christian Todd
Published Aug 17, 2026, 10:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a senior commercial officer, pre-arranged under Rule 10b5-1, which typically reduces interpretive weight versus discretionary selling.

02

Market read

Traders may note the insider sale, but there is no new fundamental information to drive a directional repricing.

03

What to watch

The filing does not state whether other insiders or the company itself made offsetting purchases, so the net insider signal is incomplete.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-17, same day as the open-market sale trades

Background

The article is an SEC Form 4 insider transaction disclosure for Alkermes plc (ALKS).

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Alkermes disclosed via Form 4 that SVP Chief Commercial Officer Nichols Christian Todd sold 7,576 shares in open-market trades on 2026-08-17 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about signaling than fundamentals.

Evidence & confidence

The filing is an insider transaction with explicit 10b5-1 pre-arrangement, and the article provides no accompanying guidance, earnings, regulatory, or deal information.

Market effects

Sector

No clear sector read-through; this is company-specific insider selling without new sector/regulatory developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Alkermes plc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Nichols Christian Todd

    SVP, Chief Commercial Officer who sold shares.

  • trading mechanism
    Rule 10b5-1 plan

    Pre-arranged plan noted as Yes, indicating scheduled trading.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALKS insider trading history →

Related articles

SEP 26
$ALKSLowAI 8/10

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

insidermonkey.com2 min
SEP 24
$ALKSMed

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

investing.com2 min
SEP 22
$ALKSMedAI 8/10

Novel First-in-Class Drug Promising in Early ADHD Study

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.

medscape.com3 min
SEP 21
$ALKSMedAI 8/10

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

Alkermes (ALKS) reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. ALKS 7290 targets the orexin 2 receptor, offering a novel approach to ADHD. The company is enrolling patients for a Phase 2 study. ALKS shares rose 1.27% to $43.95 on Monday.

benzinga.com2 min